Stockscreener 앱 받기
16.57
2.35%
0.38
시장 영업 전:
16.56
-0.01
-0.06%
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
BioAge Labs (BIOA) price target increased by 44.67% to 44.27 - MSN
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference - Bitget
BioAge CEO's April 16 fireside chat will stream live online - Stock Titan
Weekly Trades: Is BioAge Labs Inc in accumulation or distribution phaseMarket Activity Report & Free High Return Stock Watch Alerts - baoquankhu1.vn
BGE-102 data inspires confidence for BioAge Labs (BIOA) - MSN
Fund Flows: Can BioAge Labs Inc expand its profit margins2026 Selloffs & Weekly Consistent Profit Watchlists - baoquankhu1.vn
The $120 Billion Longevity Economy Is Shifting From Supplements to Therapies That Target Aging Itself — And One Small-Cap Is Producing An Anti-Aging Protein From Encapsulated Cells - Baystreet.ca
Is Amgen (AMGN) Outperforming Other Medical Stocks This Year? - Yahoo Finance Singapore
What date does BioAge Labs, Inc.'s (BIOA) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Sectors Review: Can BioAge Labs Inc expand its profit marginsOptions Play & Daily Momentum Trading Reports - baoquankhu1.vn
BioAge Labs (BIOA) CMO Rubin sells $157k in shares - Investing.com UK
BioAge Labs (BIOA) CMO Rubin sells $157k in shares By Investing.com - Investing.com South Africa
BioAge Labs (NASDAQ: BIOA) CMO exercises options, sells 8,820 shares at $17.81 - Stock Titan
Risk Hedge: How do insiders feel about BioAge Labs IncWeekly Profit Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
BIOA PE Ratio & Valuation, Is BIOA Overvalued - Intellectia AI
Short Covering: Can BioAge Labs Inc lead its sector in growthWeekly Earnings Recap & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Paul Rubin reports three 7,433-share sales (BIOA) in Form 144 - Stock Titan
BioAge Labs, Inc. (BIOA) stock price, news, quote and history - Yahoo Finance UK
BioAge Labs (NASDAQ:BIOA) Shares Up 8.7%Here's Why - MarketBeat
BGE-102 Data Inspires Confidence for BioAge Labs (BIOA) - insidermonkey.com
Market Trends: Can BioAge Labs Inc expand its profit marginsTreasury Yields & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Street Watch: Whats the beta of BioAge Labs Inc stock2026 EndofMonth & Weekly Top Stock Performers List - baoquankhu1.vn
BioAge Labs (NASDAQ:BIOA) Shares Gap UpStill a Buy? - MarketBeat
This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - benzinga.com
BioAge Labs (NASDAQ:BIOA) Coverage Initiated at Needham & Company LLC - MarketBeat
Needham Initiates BioAge Labs at Buy With $50 Price Target - marketscreener.com
Needham Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $50 - Moomoo
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Establishment Labs Holdings (ESTA) - The Globe and Mail
BioAge Labs: Early-Stage Promise in APJ Agonists Balanced by Execution Risk Supports Hold Rating - TipRanks
BioAge Highlights BGE-102 Progress and Financial Strength - The Globe and Mail
Earnings Update: How correlated is BioAge Labs Inc to the S P5002026 Fed Impact & Short-Term Trading Alerts - baoquankhu1.vn
Price Action: Can BioAge Labs Inc. lead its sector in growth2026 Review & High Accuracy Trade Alerts - baoquankhu1.vn
Oppenheimer reiterates Outperform on BioAge Labs stock at $60 By Investing.com - Investing.com India
Jefferies reiterates Buy on BioAge Labs stock citing NLRP3 progress By Investing.com - Investing.com India
Jefferies reiterates Buy on BioAge Labs stock citing NLRP3 progress - Investing.com
BioAge Labs (NASDAQ: BIOA) registers shelf for future equity and debt offers - Stock Titan
Oppenheimer reiterates Outperform on BioAge Labs stock at $60 - Investing.com
BioAge Labs Full-Year 2025 Net Loss Narrows - Moomoo
BioAge Labs (NASDAQ:BIOA) Stock Price Down 9.8%Here's Why - MarketBeat
BioAge Labs Provides Business Updates - Lifespan Research Institute
BioAge Labs Reports Positive 2025 Financial Results and Advances BGE-102 NLRP3 Inhibitor Toward Phase 2 Trials in Cardiovascular and Ophthalmology Indications - Minichart
BioAge Labs, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
BioAge Labs 2025-2026 Pipeline: Advancing BGE-102 NLRP3 Inhibitor for Cardiometabolic Disease and Ophthalmology Based on Aging Biology Insights - Minichart
BIOAGE Labs Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Form 10-K BioAge Labs, Inc. For: Dec 31 - StreetInsider
BioAge Labs (NASDAQ: BIOA) boosts R&D and outlines cash runway to 2029 - Stock Titan
Earnings Flash (BIOA) BioAge Labs Posts 2025 Collaboration Revenue $9M, vs. FactSet Est of $7.1M - marketscreener.com
Earnings Flash (BIOA) BioAge Labs Posts 2025 Net Loss $2.24 a Share, vs. FactSet Est of $1.89 Loss - marketscreener.com
1.06%
1.05%
자본화:
|
볼륨(24시간):